A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Respiratory Syncytial Virus (RSV) Infection

Interventions

BIOLOGICAL

Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)

Formulation for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (1)

Hunan Provincial Center for Disease Control and Prevention, Changsha

All Listed Sponsors

lead

Shenzhen Shenxin Biotechnology Co., Ltd

INDUSTRY